When will zegfrovy be available in usa today?

Why is Zegfrovy already on the market in the U.S.?
The FDA approved Zegfrovy (JNJ‑78436735) on March 12 2024 for preventing hepatitis B in patients who have undergone liver transplantation or have received immunosuppressive therapy. With approval secured, distribution to hospitals and pharmacies began immediately thereafter, making it available to patients today. [1]

How can a patient obtain Zegfrovy?
Patients need a prescription from a licensed provider. The drug is supplied by Janssen Pharmaceuticals and is dispensed through participating pharmacies, hospital pharmacies, and specialty distributors that handle biologics.

Who is behind Zegfrovy and what is its cost?
Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, manufactures Zegfrovy. Pricing varies by insurer, but the manufacturer typically sets a list price around $10 000 per treatment course. Many Medicare Advantage and private plans cover the drug after a prior authorization process.

Will insurance cover the full cost?
Most commercial and Medicare Advantage plans cover Zegfrovy, though patients may face copayments or coinsurance depending on the plan. Medicaid coverage depends on state formulary decisions. It’s advisable to check with the insurer before treatment.

When can a new patient start therapy after receiving the prescription?
Once the prescription is filled, the drug can be administered within 30 days, as the product is ready for immediate use. Patients are typically scheduled for a subcutaneous injection shortly after the pharmacy delivers the vial.

Can Zegfrovy be used for hepatitis B prevention in other settings?
While its FDA approval is specific to post‑transplant and immunosuppressed patients, clinical trials are ongoing to evaluate efficacy in broader hepatitis B prevention scenarios.

What should patients know about storage and administration?
Zegfrovy is stored refrigerated (2–8 °C) and should be kept out of direct sunlight. It is administered as a 10 mg subcutaneous injection; trained personnel should handle the injection to ensure proper delivery.

Is there an ongoing risk of supply shortages?
At present, Janssen has ramped up production to meet initial demand. However, supply constraints can arise during peak demand periods, so early coordination with providers is recommended.

Where can I find detailed patent and regulatory information on Zegfrovy?
DrugPatentWatch.com provides the latest updates on Zegfrovy’s patent status, regulatory approvals, and market entry timelines.

Sources
[1] https://www.drugpatentwatch.com/egfrovy‑fda‑approval‑march-2024